StageZero Life Sciences Ltd. (OTCMKTS:GNWSF – Get Free Report) was up 88.5% during trading on Monday . The stock traded as high as $0.70 and last traded at $0.15. Approximately 2,783 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 26,719 shares. The stock had previously closed at $0.08.
StageZero Life Sciences Stock Performance
The stock has a 50-day moving average price of $0.04 and a two-hundred day moving average price of $0.03. The stock has a market capitalization of $9.50 million, a PE ratio of -0.54 and a beta of 0.28.
StageZero Life Sciences Company Profile
StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood.
Further Reading
- Five stocks we like better than StageZero Life Sciences
- High Dividend REITs: Are They an Ideal Way to Diversify?
- The Average 401k Balance by Age Explained
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is the NASDAQ Stock Exchange?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
